Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder

Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder

<p>12-CK Score from RNA Sequencing</p>

Guardado en:
Detalles Bibliográficos
Autor principal: Roger Li (17078665) (author)
Otros Autores: Wade J. Sexton (17078668) (author), Jasreman Dhillon (15212961) (author), Anders Berglund (14954401) (author), Shreyas Naidu (17078671) (author), Gustavo Borjas (17078674) (author), Kyle Rose (17078677) (author), Youngchul Kim (9092151) (author), Xuefeng Wang (14955103) (author), Jose R. Conejo-Garcia (14955115) (author), Rohit K. Jain (17078680) (author), Michael A. Poch (17078683) (author), Philippe E. Spiess (17078686) (author), Julio Pow-Sang (17078689) (author), Scott M. Gilbert (17078692) (author), Jingsong Zhang (15037632) (author)
Publicado: 2025
Materias:
Cancer
Immuno-oncology
Clinical Research and Trials
Clinical Trial Results
Phase II clinical trials
Genitourinary Cancers
Bladder cancer
Immunotherapy
Checkpoint blockade
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares